Kamal Toheed
Toheed J. Kamal, MD, FRCP, FACP, FACE
Certified Internal Medicine 1989 and subspecialty of Endocrinology and Diabetes 1993 and recertified 2013
Dr. Toheed J. Kamal is a practicing endocrinologist since 1993. He did his initial medical training in England at St Thomas’s Hospital London, Glasgow Infirmary, Mansfield Hospital and Derby City Hospital.
In England, after graduation from medical school, he obtained Membership to the prestigious Royal College of Physician (MRCP) and subsequently was inducted as a Fellow to the Royal College of Physician (FRCP). He came to USA for further medical training and trained at Loyola University Chicago /Hines VA medical center and obtained his certification in Internal Medicine. Dr. Kamal completed his Endocrinology Fellowship at Northwestern university Hospital in Chicago and obtained his certification in Endocrinology and Diabetes in 1993. He has been in active clinical practice in Endocrinology and Diabetes in Alabama since that time.
Dr. Kamal area of interest includes diabetes management, thyroid, and pituitary, gonadal, adrenal and other general endocrine disorders. His experience also includes Thyroid Ultrasonography and Fine Needle Biopsy (FNA) of thyroid and parathyroid nodules.
Effect of GH binding proteins on different GH radioimmunoassays. Abstract presented at the Endocrine Society Meeting in Atlanta 1990 and published in the Journal of Clinical Endocrinology and Metabolism. Feb 91, vol 72: 387-391.
Case report of ACTH induced hypertensive episode in epinephrine producing pheochromocytoma. American Journal of Medicine. Dec 1990, vol 89: 824-825.
Effects of Calcium Channel Blockade with Verapamil on the Prolactin responses to TRH, L-Dopa and Bromocriptine. American Journal of Medical Sciences. Nov 1992, vol 304(5): 289-293.
Heterogeneity of circulating growth hormone. Abstract presented in Growth Hormone meeting in France and published in Nucl. Med. Biol. vol. 21, No. 3, pp 369-379, 1994.
Mechanism of hyperprolactinemic effects of Calcium Channel blockers, Role of tuberoin-fundibular Dopamine (TIDA) release. Accepted for publication, American Journal of Physiology.
I-131 labeled murine monoclonal antibodies to Carcino Embryonic Antigen (CEA) for imaging and immunotherapy of Medullary Thyroid Cancer. Submitted to the New England Journal of Medicine.
Effects of Ca Channel blocker on Prolactin and GH secretion in normal male volunteers. Presented at the Midwest Society of Clinical Research, April 1991.
Verapamil induced Hyperprolactinemia is due to decreased tuberoinfundibular Dopamine (TIDA) release. Presented at the 75th annual meeting of The Endocrine Society, Las Vegas, Nevada, June 1993.